Table 1 Demographic, clinical, and pathologic characteristics from 12 patients at our institution

Age, years (median [range])

70 [32, 77]

Female, n (%)

2 (18)

BMI, kg/m² (median [25%, 75%])

21.5 [18.7, 23.9]

Diabetes mellitus, n (%)

5 (45)

Hypertension, n (%)

7 (64)

Anuria, n (%)

4 (36)

Hematuria, n (%)

12 (100)

Pulmonary interstitial opacities, n (%)

3 (25)

Pulmonary hemorrhage, n (%)

2 (17)

Hemoglobin, g/dL (median [25%, 75%])

10.3 [8.3, 12.5]

Serum albumin, mg/dL (median [25%, 75%])

2.7 [2.1, 3.1]

C-reactive protein, mg/dL (median [25%, 75%])

16.7 [6.9, 28.4]

Serum creatinine, mg/dL (median [25, 75%])

8.5 [5.2, 11.4]

eGFR, ml/min/1.73 m² (median [25%, 75%])

5 [3, 8]

Baseline urine protein, g/gCr (median [25%, 75%])

1.4 [0.9, 2.4]

Anti-GBM antibody, IU/mL (median [range])

214 [43, 16,385]

MPO-ANCA positive, n (%)

2 (18)

PR3-ANCA positive, n (%)

1 (9)

MPO-ANCA, IU/mL (median [range])

40 [13.3, 67]

PR3-ANCA, IU/mL (median [range])

1.5 [1.5, 1.5]

Global sclerosis (%)

6 (55)

Crescent (%)

12 (100)

Glomerular necrosis, n (%)

10 (91)

Interstitial inflammation, n (%)

12 (100)

Normal glomeruli, n (%)

0

Plasmapheresis, n (%)

8 (73)

Number of plasmapheresis, times (median [25%, 75%])

18 [6, 20]

Oral steroids, n (%)

12 (100)

Oral steroid initial dose, mg/day (median [25%, 75%])

40 [40, 60]

Steroid pulse therapy, n (%)

10 (91)

Number of steroid pulse therapies (n = 1/2/3)

6/0/4